Serum resistin and the risk for hepatocellular carcinoma in type 2 diabetic patients
Mustafa A. Abdulhameed, Haitham A. Abdulrahmaan, Hany G. AbozaidBackground and aim
Hepatocellular carcinomas (HCCs) are the sixth most common type of cancer worldwide and the third largest cause of cancer related death. the aim of this study is To determine the relationship between serum resistin levels and the risk of HCC in type 2 diabetic patients.
Patients and methods
This case–control prospective study was conducted on 100 volunteers recruited from the Internal Medicine Department, Al-Azhar University Hospital. All participants were divided into two groups: Group I (
Results
The area under the curve, sensitivity, and specificity of resistin were 0.940, 80%, and 85%, respectively. All cases in group II (non-HCC group) had Child–Pugh score A.
Conclusions
For patients with HCC, serum resistin levels may be a novel diagnostic sign with strong predictive values at a cutoff of more than 277.5 in HCC prediction. The area under the curve, sensitivity, and specificity of resistin are 0.940, 80%, and 85%, respectively. HCC diabetic patients have higher systolic and diastolic blood pressure, lower hemoglobin and white blood cells, higher liver and kidney function tests, and higher Child score than non-HCC cirrhotic diabetic patients.